Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives

paythelady.612 shared this article with you from Inoreader Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 May 6;9(13):2951-2968. doi: 10.12998/wjcc.v9.i13.2951. ABSTRACT The outbreak of coronavirus disease-2019 (COVID-19) has resulted in a global public health emergency. Patients with cirrhosis were deemed more susceptible to viral infection because of their dysregulated immune response. Similar to the general population, cirrhotic patients exhibit various degrees of COVID-19-related liver injury, which could be attributed to direct virus cytotoxicity, systemic immune system activation, drug-related liver injury, reactivation of pre-existing liver disease, and hypoxic hepatitis. The clinical symptoms in patients with cirrhosis and COVID-19 were similar to those in the general population with COVID-19, with a lower proportion of patients with gastrointestinal symptoms. Although respiratory failure is the predominant cause of mortality in cirrhotic patients with COVID-19, a significant proportion of them lack initial respiratory symptoms. Most evidence has shown that cirrhotic patients have relatively higher rates of morbidity and mortality associated with COVID-19. Advanced cirrhosis was also proposed as an independent factor affecting a poor prognosis and the need to consider COVID-19 palliative care. General measures implemented to prevent the transmission of the virus are also essential for cirrhotic patients, and they should also receive standard cirrhosis care with minimal interruptions. The efficacy of the available COVID-19 vaccines in cirrhotic patients still needs investigation. PMID:33969082 | PMC:PMC8080735 | DOI:10.12998/wjcc.v9.i13.2951 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.